By Zoila Palma: Four patients in Denmark have been granted compensation after experiencing vision loss allegedly connected to the use of Novo Nordisk’s popular medications Wegovy and Ozempic, the Danish Patient Compensation Association announced Friday.
The drugs, which contain semaglutide, were linked earlier this year to rare cases of non-arteritic anterior ischemic optic neuropathy (NAION), a serious condition that can lead to permanent vision loss, according to the European Medicines Agency, Reuters report.
Following the EMA’s review, Novo Nordisk updated the safety labels for both medications, noting that NAION may occur in up to 1 in 10,000 patients.
Of 43 claims submitted to the compensation association, five have so far been adjudicated—four approved, resulting in a combined payout of 800,000 Danish crowns (approximately $123,000), and one dismissed.
The state covers compensation awarded through the association, which said the cases required complex assessments and expert input from an optic nerve specialist.
Novo Nordisk responded by emphasizing its commitment to safety, stating that it continues to view semaglutide’s benefit-risk profile as favorable.
The post International News: Denmark awards compensation to patients reporting vision loss linked to Novo Nordisk drugs appeared first on Belize News and Opinion on www.breakingbelizenews.com.
By Zoila Palma: Four patients in Denmark have been granted compensation after experiencing vision loss allegedly connected to the use of Novo Nordisk’s popular medications Wegovy and Ozempic, the Danish Patient Compensation Association announced Friday. The drugs, which contain semaglutide, were linked earlier this year to rare cases of non-arteritic anterior ischemic optic neuropathy (NAION),
The post International News: Denmark awards compensation to patients reporting vision loss linked to Novo Nordisk drugs appeared first on Belize News and Opinion on www.breakingbelizenews.com.
